Zai Lab (ZLAB) and Pfizer (PFE) announced a strategic collaboration for the novel antibacterial drug Xacduro in mainland China. Pfizer’s affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for Xacduro in mainland China. Through this collaboration, Zai Lab will leverage the commercialization infrastructure of Pfizer’s affiliated companies in the anti-infective therapeutic area to help accelerate access to this important therapy for patients in need in mainland China. The period of collaboration is for the imported product through November 2028, subject to early termination or extension.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZLAB:
- Zai Lab 7.84M share Secondary priced at $25.50
- Zai Lab announces $200M American depositary shares offering
- Zai Lab Reports Strong Q3 Growth and Pipeline Progress
- Zai Lab reports Q3 EPS (42c), consensus (78c)
- Argenx, Zai Lab announce approval of VYVGART Hytrulo in China
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
